| Market Capitalization (Millions $) |
13,600 |
| Shares
Outstanding (Millions) |
103 |
| Employees |
202 |
| Revenues (TTM) (Millions $) |
681 |
| Net Income (TTM) (Millions $) |
-75 |
| Cash Flow (TTM) (Millions $) |
159 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Intra cellular Therapies Inc (ITCI) is a biopharmaceutical company that is focused on the discovery and development of molecular drugs that target the central nervous system (CNS). The company's mission is to develop innovative therapies that can improve the lives of patients with serious neurological and psychiatric disorders. The company is based in New York and was founded in 200
ITCI's therapies are based on the science of phospholipid signaling. Phospholipids are important molecules that are present in the membranes of cells. They play a key role in cell to cell communication by signaling within and between cells. ITCI has developed drug candidates that target specific pathways in the brain that are controlled by these signaling molecules. These pathways have been implicated in a range of psychiatric and neurological disorders including schizophrenia, bipolar disorder, depression, and Alzheimer's disease.
The company's lead drug candidate is Lumateperone, which is an oral medicine that has been developed for the treatment of schizophrenia. It is designed to balance the activity of neurotransmitters in the brain, which can help to reduce the symptoms of schizophrenia, such as hallucinations and delusions. Lumateperone has completed three phase-3 clinical trials, and the results have been positive. The drug was granted FDA approval in December 2019.
ITCI has also developed other drug candidates for the treatment of major depressive disorder, bipolar disorder, and other neurological conditions such as Alzheimer's disease. The company has a deep pipeline of CNS-focused drug candidates, which is supported by a strong intellectual property portfolio.
In addition to its drug development efforts, ITCI is also engaged in research and development of digital therapeutics. These are software-based interventions that are designed to improve patient outcomes by providing targeted support, education, and engagement. ITCI is exploring the potential for digital therapeutics to complement its drug therapies.
In summary, Intra cellular Therapies Inc is a biopharmaceutical company that is focused on the discovery and development of innovative therapies for serious neurological and psychiatric disorders. The company has developed drug candidates that target specific pathways in the brain that are controlled by phospholipid signaling. These therapies have the potential to improve patient outcomes and fill unmet medical needs in this area.
Company Address: 135 Route 202/206, Suite 6 Bedminster 7921 NJ
Company Phone Number: 440-9333 Stock Exchange / Ticker: NASDAQ ITCI
|
0.38% 